IVI’s Jennifer Bright and Mark Linthicum write in STAT News that we’re squandering time and resources trying to find a neat answer to “what is value?” by focusing on the cost of drugs without tackling other hard questions at the heart of measuring value across healthcare interventions. Determining the value of health care, they argue, [...]
IVI’s Jennifer Bright the president of the Institute for Integrated Benefits, Tom Parry, Ph.D., write in Fierce Healthcare that most employers have no idea how their benefit programs affect employee health outcomes. They outline a set of guiding principles to help employers take a more holistic approach – and foster a healthy, productive workforce – [...]
Value-based healthcare is predicated on collaboration. Sharing of data, methods, pathways and perspectives among different stakeholders is paramount if the transition to value-based care is to be fully realized. Instead of relying solely on legacy methods to measure value, IVI's Open-Source Value Platform (OSVP) uses a transparent and open-source process to develop methods and tools [...]
IVI's Director of Scientific Communications, Mark Linthicum, sits down with the Journal of Clinical Pathways for a webinar discussion about IVI's open-source model for assessing value in non-small cell lung cancer therapies. If you want to learn more about IVI's open-source approach to value assessment, this webinar is a great place to start. Click here to [...]
IVI will host two upcoming webinars focused on its new disease-specific, open-source value model to assess EGFR+ non-small cell lung cancer (NSCLC) therapy sequences. These webinars are free and open to the public. We hope you will join us to learn more about IVI's Open-Source Value Project (OSVP) and the new IVI-NSCLC model. Detailed information and [...]
IVI released our initial version of the new Open-Source Value Platform (OSVP) model for non-small cell lung cancer. Specifically, the model provides information on the relative value of sequential treatments for epidermal growth factor receptor positive (EGFR+), non-squamous non-small cell lung cancer (NSCLC). The entirety of the IVI-NSCLC model package, including detailed methods documentation, R [...]
In a Morning Consult commentary, IVI Executive Director, Jennifer Bright, discusses why transparency is a prerequisite to value-based reimbursement and how IVI's Open-Source Value Platform (OSVP) is an open laboratory for creating sophisticated systems to assess value in healthcare. Read the full article here.
In an article published online by the American Journal of Managed Care, IVI's Executive Director, Jennifer Bright, and Director of Scientific Communications, Mark Linthicum, offer five predictions for where value assessment is headed in 2019. Specifically, Jennifer and Mark focus their discussion on the following areas of interest regarding value assessment: Including patient perspectives becomes [...]
IVI research into six pre-2016 ICER studies reveals an overestimation of “unmanaged” drug use and drug cost trends. The peer-reviewed research, published in Value in Health, illustrates the difficulty in predicting budget impact and the consequences of not accounting for uncertainty in value assessment. Read the full article here.
Value Frameworks Must Incorporate Real-World Evidence, Says Research Team Including IVI’s Darius Lakdawalla and Wayne Burton
In a new paper published by the American Journal of Managed Care, a team of researchers, including IVI's Darius Lakdawalla and Wayne Burton, conclude that key decision makers within our healthcare system need to recognize the importance of implementing real-world evidence and devote resources to further research into the chronic disease areas in which the [...]